HOME >> MEDICINE >> NEWS
Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis

San Francisco, Calif., May 23, 2001 Data from a study presented today at the 97th annual meeting of the American Thoracic Society show that patients who were treated with clarithromycin (Biaxin, Abbott Laboratories) for an acute exacerbation of chronic bronchitis (AECB), experienced a higher rate of improvement and fewer adverse events than patients who were treated with other leading antibiotics, including levofloxacin (Levaquin, Johnson & Johnson) and cefuroxime axetil (Ceftin, GlaxoSmithKline).

According to the study results, more patients with chronic bronchitis who were treated with clarithromycin improved compared to patients treated with the other antibiotics, said Lee R. Weiss, M.D., F.A.C.E.P., chairman, department of emergency medicine, Knox Community Hospital, Mount Vernon, Ohio, and lead investigator of the study. Specifically, clarithromycin offers an important alternative in the treatment arsenal for patients with an acute exacerbation of chronic bronchitis, as it offers a higher cure rate and fewer side effects.

Study Results

A randomized, prospective, multi-center study of 283 patients, compared clarithromycin 500 mg BID, levofloxacin 500 mg QD, and cefuroxime axetil 250 mg BID in patients with AECB. Each drug was administered for 10 days. For six weeks prior to randomization, patients with suspected AECB completed a questionnaire designed to assess disease severity and antimicrobial treatment. Eligible patients were required to have chest radiographs negative for pneumonia or structural lung disease (other than chronic obstructive pulmonary disease).

Among the eligible patients, 97 were randomized to clarithromycin, 94 to levofloxacin, and 92 to cefuroxime axetil. No significant difference was observed in disease between any groups at the start of the study. Among evaluable patients, clinical cure/improvement was observed in 87.9 percent (80 of 91) of those treated with clarithromycin, 87.3 percent (76 of 87) of tho
'"/>

Contact: Donna Lindquist
312-856-8873
Porter Novelli
22-May-2001


Page: 1 2

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher doses of cancer drug imatinib proven effective and safe
5. Higher dose of Gleevec leads to increased remission in CML patients
6. Higher education or larger brain size may protect against dementia later in life, new study finds
7. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
8. Higher nocturnal blood pressure predictive of kidney disease in diabetes
9. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... Md. (PRWEB) , ... February 19, 2019 , ... ... Alan Einhorn, both of counsels to Foley & Lardner LLP, as Recognized Consultants. ... and digital health companies, interested in pursuing CHQI accreditation. , Ms. Wein ...
(Date:2/19/2019)... ... 19, 2019 , ... Reproductive Biology Associates (RBA), ... and a part of the Prelude Fertility (Prelude) network, announces today ... Hospital. , The only reproductive endocrinology practice on the Piedmont Atlanta hospital campus, ...
(Date:2/19/2019)... ... February 18, 2019 , ... ... U.S. Patent No. 10,195,147 titled, “Dry powder aspirin compositions with magnesium stearate,” protect ... also protected by three previously granted utility patents, two issued by the USPTO ...
(Date:2/19/2019)... ... February 19, 2019 , ... K.J. Kidd, a Missouri native born ... a Missed Opportunity”: an autobiographical work offered to encourage other women to be proactive ... , Kidd shares, “On September 28th of 2013, I spent my entire morning walking ...
(Date:2/19/2019)... ... , ... Diploid , leading AI-based software provider for rare disease diagnostics, ... into a partnership to improve genome interpretation for rare disease diagnostics. , With its ... Moon allows its users to go from VCF to causal variant in just minutes ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... February 19, 2019 , ... ... Senior Vice President. Kunney, based in Atlanta, is an experienced IT leader ... that effectively integrate within the clinical setting. He works with hospitals, health ...
(Date:2/19/2019)... SEATTLE (PRWEB) , ... February 19, 2019 , ... ... device company developing non-invasive treatments for cancers and other serious diseases, today announced ... early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is ...
(Date:2/19/2019)... GREENVILLE, S.C. (PRWEB) , ... February 19, 2019 , ... ... North America for the scientific development, healthcare training and clinical application of medical infrared ... take place on September 7-8 at the Emory University Conference Center in Atlanta, GA. ...
Breaking Medicine Technology:
Cached News: